Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Plasma-Cell Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT01931644
What this trial is testing

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Who this might be right for
All Diagnosed Health ConditionsADD/ADHDAlopecia Areata+58 more
Sanguine Biosciences 17,667
Early research (Phase 1)Looking for participantsNCT07139509
What this trial is testing

Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma(MM)
Xi'an No.3 Hospital 18
Testing effectiveness (Phase 2)WithdrawnNCT05393999
What this trial is testing

SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations

Who this might be right for
SARS-CoV2 InfectionSARS-CoV-2 Acute Respiratory DiseaseMyeloma+4 more
Imperial College Healthcare NHS Trust
Not applicableLooking for participantsNCT02012699
What this trial is testing

Integrated Cancer Repository for Cancer Research

Who this might be right for
Pancreatic CancerThyroid CancerLung Cancer+47 more
University of Nebraska 999,999
Early research (Phase 1)Study completedNCT00060632
What this trial is testing

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Who this might be right for
TumorsLymphomaMultiple Myeloma
Merck Sharp & Dohme LLC 46
Large-scale testing (Phase 3)Ended earlyNCT03440411
What this trial is testing

Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment

Who this might be right for
Multiple Myeloma
Fondazione EMN Italy Onlus 9
Early research (Phase 1)WithdrawnNCT01452334
What this trial is testing

Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy

Who this might be right for
Non-Hodgkin's LymphomaHodgkin LymphomaMultiple Myeloma+1 more
Bristol-Myers Squibb
Early research (Phase 1)Study completedNCT01588015
What this trial is testing

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+123 more
City of Hope Medical Center 36
Large-scale testing (Phase 3)Looking for participantsNCT07202065
What this trial is testing

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Who this might be right for
MyelomaNon Hodgkin's LymphomaLeukemia
Monash University 900
Early research (Phase 1)Study completedNCT01998971
What this trial is testing

JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 240
Early research (Phase 1)Study completedNCT02095834
What this trial is testing

Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
M.D. Anderson Cancer Center 18
Large-scale testing (Phase 3)Active Not RecruitingNCT04923893
What this trial is testing

Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 743
Early research (Phase 1)Ended earlyNCT04892264
What this trial is testing

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Who this might be right for
Plasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Mayo Clinic 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT03271632
What this trial is testing

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shenzhen Geno-Immune Medical Institute 20
Early research (Phase 1)Study completedNCT03042793
What this trial is testing

Vaccination With PD-L1 Peptide Against Multiple Myeloma

Who this might be right for
Multiple Myeloma
Lene Meldgaard Knudsen 10
Not applicableStudy completedNCT06359067
What this trial is testing

A Real-World Study of Bispecific Antibodies in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Assistance Publique - Hôpitaux de Paris 600
Not applicableStudy completedNCT00281814
What this trial is testing

Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
The Cleveland Clinic 36
Testing effectiveness (Phase 2)Study completedNCT02858999
What this trial is testing

Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70

Who this might be right for
Multiple Myeloma
Centre Hospitalier Universitaire, Amiens 40
Not applicableUnknownNCT05893693
What this trial is testing

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Relapsed and/or Refractory Multiple MyelomaPlasma Cell Leukemia in Relapse
Aibin Liang，MD，Ph.D. 12
Testing effectiveness (Phase 2)Study completedNCT03430011
What this trial is testing

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene 165
Next Page